Protein filaments in the regulation of gene expression

Although every cell in our body contains the same genetic information, cells differ in the way they use it, a process known as “gene expression”. The regulation of gene expression is orchestrated by proteins called transcription factors, which bind to specific sequences within DNA. Transcription factors are traditionally thought to operate mainly as single molecules or dimers.

The article by Mance et al. reveals that several transcription factors of the family known as ZBTB, present in humans and other animals, have the capacity to form non-covalent filamentous structures composed of numerous identical copies of proteins arranged in a chain. At the molecular level, such structures could offer significant advantages for binding to DNA, which is itself an elongated molecule containing numerous repeated sequences. A few examples of filament-forming transcription factors had already been reported, but this study extends the concept to a large family of this protein with important functions. The study - which combines structural, biophysical and functional analysis carried out in vitro and in cells - was carried out by the "Post-translational modifications and DNA repair" team at the CBM and their collaborators in Orléans, Rennes and Marseille, including the "Functional mass spectrometry of molecular assemblies" team also at the CBM.

The findings from this research, together with a complementary study by groups of Benjamin Ebert and Eric Fischer from Dana-Farber Cancer Institute at Harvard (published back-to-back in the same issue of Molecular Cell), challenge the traditional view of transcription factor functionality.

In cells, ZBTB proteins are regulated through a process called SUMOylation, where a small tag called SUMO is added to them, changing how they function. Studies on ZBTB proteins undertaken in Orléans, during which the filamentous structures were discovered, are part of the "SUMOwriteNread" project funded by the European Union (ERC grant no 101078837). Researchers are currently investigating the interplay between the ability to form filaments and SUMO tagging to understand the complex reality of gene expression regulation.

This research was reported by CNRS Chimie on its website.

Dynamic BTB-domain filaments promote clustering of ZBTB proteins.
Lucija Mance, Nicolas Bigot, Edison Zhamungui Sánchez, Franck Coste, Natalia Martín-González, Siham Zentout, Marin Biliškov, Zofia Pukało, Aanchal Mishra, Catherine Chapuis, Ana-Andreea Arteni, Axelle Lateur, Stéphane Goffinont, Virginie Gaudon, Ibtissam Talhaoui, Ignacio Casuso, Martine Beaufour, Norbert Garnier, Franck Artzner, Martine Cadene, Sébastien Huet, Bertrand Castaing & Marcin Józef  Suskiewicz
Molecular Cell 2024
https://doi.org/10.1016/j.molcel.2024.05.029

CNRS Chimie Emergence@International

Federico Perche, a researcher in the "MACS : Molecular Assemblies and Complex Systems" team, has been awarded CNRS Chimie Emergence@International.

He will be going to the United States to develop research collaborations in his field of mRNA and siRNA delivery.

During a 2-week stay, he will visit the Universities of San Diego (Pr Kwon and  Pr Shresta, Arizona (Dr Liu), Texas A&M (Dr Zhu) and Chicago (Dr Voth).

Federico has started a collaboration with Dr Shresta on mRNA vaccination and is looking to develop new collaborations.

Details of the 4 thesis offers:

Thesis subject: "Suffering at work and consumption of psychoactive substances among territorial agents of the Communauté de commune des Terres du Val de Loire (TraPsyCOL)"
Supervisor: Raphaël Serreau, Neurobiology of receptors and therapeutic innovations team
View the offer

Thesis subject: "Molecular assembly of synthetic microRNAs in intracellular condensates of human glioblastoma cells"
Supervisors: Patrick Baril and Séverine Morisset-Lopez, Neurobiology of receptors and therapeutic innovations team
View the offer

Thesis subject: "Discovery and total chemical synthesis of D-proteins for molecular targeting of tumor glyco-epitopes"
Supervisors: Vincent Aucagne and Carlo Pifferi, Synthetic proteins and bioorthogonal chemistry team
View the offer

Thesis subject: "Anti-hOGG1 nanobodies to study the interactions between DNA repair and transcription regulation and to modulate the action of hOGG1 in anti-cancer strategies"
Supervisor: Bertrand Castaing, “Post-translational modifications of proteins and DNA repair: structure, functions and dynamism” team
View the offer

La ligue contre le Cancer (The League Against Cancer) supports research carried out at the CBM

Each year, the Grand Ouest Committee of the League Against Cancer actively participates in research by financing a certain number of scientific projects. At the start of 2024, he donated €84,000 to CBM researchers.

3 projects, at the cutting edge of cancer research, have been funded.

"New therapeutic approach in oncology: development of PROTACs targeting LIMK1 and LIMK2 kinases"
Leader: Béatrice Vallée co-leader of the “Cell signaling and neurofibromatosis” team
Partner: Karen Plé, ICOA, UMR7311, CNRS/University of Orléans

The protein kinases, LIMK1 and LIMK2, are involved in cell skeletal remo Their active role in the development of cancers has been shown both in the formation of tumors and in their dissemination and the growth of metastases. Targeting LIMK1 and LIMK2 to develop new anti-cancer therapies is therefore a very relevant strategy.Unfortunately, traditional small chemical molecules inhibiting the activity of LIMK1 and LIMK2 have not passed clinical trials.In our project, we therefore decided to develop a new class of molecules, PROTACs, which allow the destruction of their target directly in the cell. In our case, we target the destruction of LIMK1 and LIMK2 to annihilate their oncological activity. This PROTAC strategy is very innovative and growing. Building on very promising results that have been obtained on other therapeutic targets, we hope to demonstrate the proof of concept of this new approach targeting LIMK1 and LIMK2, and thus open the way to new therapeutic molecules.

This project received the support of the League against Cancer, the Committees of Loiret, Loir-et-Cher and Morbihan, for the sum of €32,000.

“Innovative prostate cancer diagnosis for personalized medicine approaches: intelligent multiplex mapping of SKCa channels using near-infrared emitting lanthanide-based metallacrowns”
Leader: Svetlana ELISEEVA, “Luminescent lanthanide compounds, spectroscopy and optical bioimaging” team

Each patient's tumors are different because each individual is different. It is therefore crucial to take this diversity of tumors into account to develop personalized approaches. Our research work aims to characterize cancerous tumors with the aim of providing more effective treatment to cure cancer.Several specific potassium channels play a major role in the progression of cancerous tumors and are sensitive to therapies. In this project, we are implementing an innovative near-infrared optical imaging approach which will make it possible to establish the precise identity map of these potassium channels for each patient in order to provide personalized treatment.

This project received the support of the League against Cancer of the Committees of Loiret, Loir-et-Cher and Sarthe, for the sum of €30,000.

“Cancer immunotherapy: evaluation of synthetic versus in-cell expressed bispecific di-affibodies”
Leader: Josef Hamacek, head of the “Molecular assemblies and complex systems” team
Partners: Federico Perche, Vincent Aucagne (CBM), Florence Velge-Roussel (NMNS Tours)

Several receptors on the surface of cancer cells may represent potential targets for antibodies with broad neutralization spectrum. The principle of bispecific synergistic antibodies is to bind via a binding site on the surface of the tumor cell and with the other site to a receptor on the surface of the immune effector cell (NK, T lymphocytes).In this context, antibodies can be replaced by affibodies (AfBs) presenting affinities and selectivities for their targets comparable to antibodies, but having smaller size.This project aims to develop bispecific di-AfBs as innovative agents for the diagnosis and immunotherapy of cancer.These complex molecules are made up of two AfBs linked by linkers and can thus target two epitopes. AfBs will bind specifically to the corresponding receptors overexpressed on the surface of cancer cells to block signaling pathways, and to promote the recruitment of effector cells.This concept offers new therapeutic perspectives and makes it possible to optimize interactions with the cell and provoke the immune reaction.

This project received support from the League Against Cancer of the Committees of Loiret, Sarthe and Côtes d’Armor, for the sum of €22,000.